APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

ABSTRACT:

Background

Cognitive decline is well recognized in Parkinson's disease (PD) and a major concern for patients and caregivers. Apolipoprotein E (APOE), catechol-O-methyl transferase (COMT), and microtubule-associated protein tau (MAPT) are of interest related to their contributions to cognitive decline or dementia in PD.

Objective

Here, we investigate whether APOE, COMT, or MAPT influence the rate of cognitive decline in PD patients.

Methods

We relied on 634 PD patients and 879 controls to examine gene-PD susceptibility associations, and nested longitudinal cohort of 246 patients from the case-control study, which followed patients on average 5 years and 7.5 years into disease. We repeatedly assessed cognitive symptom progression with the MMSE and conducted a full neuro

SUBMITTER: Paul KC 

PROVIDER: S-EPMC5927361 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature